[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-381933-105":59,"doc-detail-381933-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","immune-related-adverse-events-and-clinical-outcomes-in-advanced-urothelial-cancer-patients-treated-with-immune-checkpoint-inhibitors","Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors","","Background: In advanced urothelial cancers, immune checkpoint inhibitors (ICI) provide durable therapy, but immune-related adverse events (irAEs) may reflect treatment benefit. Materials and Methods: A retrospective cohort of 70 advanced urothelial cancer patients treated with ICIs at Winship Cancer Institute (2015–2020) was analyzed using Cox proportional hazards and logistic regression for overall survival (OS), progression-free survival (PFS), and clinical benefit (CB), with extended Cox models to address lead-time bias. Results: Patients with any irAE showed improved OS, PFS, and CB, with dermatologic irAEs also associated with superior outcomes. Conclusion: irAEs, particularly dermatologic events, may serve as markers of durable response, warranting validation in larger studies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/immune-related-adverse-events-and-clinical-outcomes-in-advanced-urothelial-cancer-patients-treated-with-immune-checkpoint-inhibitors/381933/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/immune-related-adverse-events-and-clinical-outcomes-in-advanced-urothelial-cancer-patients-treated-with-immune-checkpoint-inhibitors/381933.png","ImageObject",300,407,{"name":92,"@type":93},"Anna Hans","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-26","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":14},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the study’s objective regarding immune-related adverse events (irAEs)?","Question",{"text":112,"@type":113},"To investigate the relationship between irAEs and clinical outcomes in advanced urothelial cancer patients treated with immune checkpoint inhibitors (ICIs).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many patients were included, and what treatment period was analyzed?",{"text":117,"@type":113},"Seventy patients were included, with treatment data collected from 2015 to 2020 at Winship Cancer Institute.",{"name":119,"@type":110,"acceptedAnswer":120},"What clinical outcomes were associated with experiencing an irAE?",{"text":121,"@type":113},"Patients with at least one irAE had significantly improved overall survival (OS), progression-free survival (PFS), and clinical benefit (CB), and dermatologic irAEs also showed significant associations.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},381933,1790381190,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":14,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},5909892332657,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors  \nGregory E. Sanda1,2,‡, Julie M. Shabto1,2,‡, Subir Goyal3, Yuan Liu3, Dylan J. Martini4, Bassel Nazha1,2, Jacqueline T. Brown1,2, Lauren B. Yantorni1,2, Greta Anne Russler1,2,  \nSarah Caulfield1,5, Shreyas S. Joshi6, Vikram M. Narayan6, Haydn Kissick2,6, Kenneth Ogan2,6, VirajA. Master6, Bradley C. Carthon1,2, Omer Kucuk1,2, Mehmet Asim Bilen*, 1,2  \n1Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA 2Winship Cancer Institute of Emory University, Atlanta, GA, USA  \n3Departments of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA 4Department of Medicine, Massachusetts General Hospital, Boston, MA, USA  \n5Department of Pharmaceutical Services, Emory University School of Medicine, Atlanta, GA, USA 6Department of Urology, Emory University School of Medicine, Atlanta, GA, USA  \n* Corresponding author: Mehmet Asim Bilen, MD, Associate Professor, Director, Genitourinary Medical Oncology Program, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, 1365B Clifton Road NE, Suite B4000, Office 4212, Atlanta, GA 30322, USA. Tel: +1 404 778 3693;  \nFax: +1 404 778 8584; [Email:](Email: mehmet.a.bilen@emory.edu)[ mehmet.a.bilen@emory.edu](Email: mehmet.a.bilen@emory.edu)[ ](Email: mehmet.a.bilen@emory.edu)‡Co-first authors.  \nAbstract  \nBackground: In advanced urothelial cancers (UC), immune checkpoint inhibitors (ICI) show promise as a durable therapy. Immune-related adverse events (irAEs), a side effect of ICIs, may serve as an indicator of beneficial response. We investigated the relationship between irAEs and clinical outcomes in patients with advanced UC who received ICI.  \nMaterials and Methods: In this retrospective study, we investigated 70 patients with advanced UC treated with ICIs at Winship Cancer Institute from 2015 to 2020. Data on patients were collected through chart review. Cox’s proportional hazard model and logistic regression were applied to estimate the association with overall survival (OS), progression-free survival (PFS), and clinical benefit (CB) . The possible lead-time bias was handled in extended Cox regression models.  \nResults: The median age of the cohort was 68. Over one-third (35%) of patients experienced an irAE, with skin being the most frequent organ involved (12 .9%) . Patients that experienced at least one irAE had significantly enhanced OS (HR: 0.38, 95% CI, 0.18-0.79, P = .009), PFS (HR: 0.27, 95% CI, 0.14-0. 53, P \u003C .001), and CB (OR: 4.20, 95% CI, 1.35-13.06, P = .013) . Patients who experienced dermatologic irAEs also had significantly greater OS, PFS, and CB.  \nConclusion: Of patients with advanced UC that had undergone ICI therapy, those who had irAEs, especially dermatologic irAEs, had significantly greater OS, PFS, and CB. These results may suggest that irAE’s may serve as an important marker of durable response to ICI therapy inurothelial cancer. The findings of this study need to be validated with larger cohort studies in the future.  \nKey words: immune-related adverse events; urothelial cancer; bladder cancer; checkpoint inhibitor; outcomes.  \nImplications for Practice  \nThis study found that patients with advanced urothelial cancer undergoing ICI who experienced irAEs, especially those of the skin, had significantly improved clinical outcomes compared to those who did not experience an irAE. With the increasing use of ICIs in urothelial cancers, our results suggest the occurrence of an irAE, particularly in the skin, may act as a clinical marker of beneficial therapy response and improved outcome for that patient.  \nIntroduction  \nBladder cancer is a common and complex disease that requires multidisciplinary specialties for optimal treatment. There are approximately 81 000 new cases and 17 000 deaths in the  \nUS, and over 700 000 cases estimated wor","cbCaimHICc3XSV1z","https://ap.wps.com/l/cbCaimHICc3XSV1z","pdf",387527,"English","# Abstract\n## Background\n## Materials and Methods\n## Results\n## Conclusion\n# Implications for Practice\n# Introduction","[{\"question\":\"What was the study’s objective regarding immune-related adverse events (irAEs)?\",\"answer\":\"To investigate the relationship between irAEs and clinical outcomes in advanced urothelial cancer patients treated with immune checkpoint inhibitors (ICIs).\"},{\"question\":\"How many patients were included, and what treatment period was analyzed?\",\"answer\":\"Seventy patients were included, with treatment data collected from 2015 to 2020 at Winship Cancer Institute.\"},{\"question\":\"What clinical outcomes were associated with experiencing an irAE?\",\"answer\":\"Patients with at least one irAE had significantly improved overall survival (OS), progression-free survival (PFS), and clinical benefit (CB), and dermatologic irAEs also showed significant associations.\"}]","Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors | PDF",1790247865,18]